Savolitinib is a MET receptor inhibitor that specifically inhibits MET activation by disrupting the MET signal transduction in an adenosine triphosphate competitive regime, whereby it inhibits the tumor cell growth [165]. This evidence concerns the gene MET and neoplasm.